Inhibition of telomerase activity by telomerase inhibitors induces a gradual loss of telomeres, and this in turn causes cancer cells to enter to a crisis stage. Here, we report the telomerase inhibitor telomestatin, which is known to stabilize G-quadruplex structures at 3 0 single-stranded telomeric overhangs (G-tails), rapidly dissociates TRF2 from telomeres in cancer cells within a week, when given at a concentration that does not cause normal cells to die. The G-tails were dramatically reduced upon short-term treatment with the drug in cancer cell lines, but not in normal fibroblasts and epithelial cells. In addition, telomestatin also induced anaphase bridge formation in cancer cell lines. These effects of telomestatin were similar to those of dominant negative TRF2, which also causes a prompt loss of the telomeric G-tails and induces an anaphase bridge. These results indicate that telomestatin exerts its anticancer effect not only through inhibiting telomere elongation, but also by rapidly disrupting the capping function at the very ends of telomeres. Unlike conventional telomerase inhibitors that require long-term treatments, the G-quadruplex stabilizer telomestatin induced prompt cell death, and it was selectively effective in cancer cells. This study also identifies the TRF2 protein as a therapeutic target for treating many types of cancer which have the TRF2 protein at caps of the telomere DNA of each chromosome.
Introduction
Telomeres are special structures at the ends of chromosomes that are essential for stabilizing linear chromosomes. One major strategy to impair telomere function is to inhibit telomerase, which synthesizes 5 0 -TTAGGG-3 0 telomeric DNA de novo. Expression of the catalytic subunit of the telomerase gene, hTERT, is strongly correlated with telomerase activity. Introduction of the hTERT gene into normal cells induces telomerase activity followed by telomere elongation, as well as lifespan extension in vitro (Bodnar et al., 1998) . The hTERT-immortalized cells have a very similar phenotype to normal cells with respect to morphology, cell growth, contact inhibition and other fundamental functions, with the exception of lifespan (Carney et al., 2002) . On the other hand, ectopic expression of dominant-negative hTERT in telomerase positive cancer cell lines induces telomere shortening with each cell division, leading to cell death or differentiation (Kondo et al., 1998; Hahn et al., 1999; Zhang et al., 1999) . These results show that telomerase inhibitors might compromise tumor growth by accelerating telomere shortening, which will cause cell death due to the limitation of telomere length. Treatment of human monoblastoid leukemia U937 cells with a nontoxic dose of MST-312 caused progressive telomere shortening and eventual reduction of the cellular growth rate, which was accompanied by induction of senescence-associated b-galactosidase activity (Seimiya et al., 2002) . The lethal effect of telomerase inhibitors on cancer cells is likely to depend on telomere length, since cancer cell lines with long telomeres require much time to be killed by GRN163 which is 13-mer 2 0 -deoxyoligonucleotide N3 0 P5 0 thiophosphoramidate targeting human telomerase RNA component (hTR) (Akiyama et al., 2003) . In fact, apoptosis of cancer cells by a dominant-negative hTERT must await telomere shortening, and therefore the time lag for cell death is attributed to telomere length.
Telomeric DNA is composed of tandem repeats of 3-20 kb G-rich duplex sequences with a G-rich 3 0 overhang averaging 130-210 bases in length (Makarov et al., 1997; Wright et al., 1997) . The 3 0 overhang of human telomeres has been shown to form tetra-stranded DNA structures, termed G-quadruplexes. The 3 0 overhang can fold into at least two different intramolecular quadruplexes that differ in the positions of the adjacent loop regions (Parkinson et al., 2002) . G-quadruplex structures have been implicated in the elongation of telomeric DNA by telomerase (Han and Hurley, 2000) . The nonfolding single-stranded telomere overhang is required for an optimal telomerase reaction, and G-quadruplex formation has been shown to inhibit telomerase elongation in vitro (Zahler et al., 1991) . Agents that stabilize G-quadruplexes have the potential to interfere with telomere replication by blocking the elongation step catalysed by telomerase, and thus are very attractive targets for drug design (Mergny and Helene, 1998) . Small molecular ligands that selectively stabilize the telomeric G-quadruplex induce telomere shortening and replicative senescence (Han and Hurley, 2000; Gowan et al., 2001 Gowan et al., , 2002 Riou et al., 2002) .
Telomestatin, a G-quadruplex interacting agent, is a natural product that was isolated from Streptomyces nanulatus 3533-SV4 by screening using a telomeric repeat amplification protocol (TRAP) assay, and it has been shown to be a very potent telomerase inhibitor (Shin-ya et al., 2001) . Telomestatin also enhances stabilization of telomeric G-quadruplex DNA and inhibits the polymerase reaction. Thus, telomestatin blocks the elongation of telomeric DNA by telomerase. In the BCR-ABL-positive leukemic cell lines OM9;22 and K562, telomestatin inhibits telomerase activity, resulting in telomere shortening and ultimately telomere dysfunction (Tauchi et al., 2003) . Telomestatin interacts preferentially with intramolecular versus intermolecular G-quadruplex structures (Kim et al., 2002) . Telomestatin is able to stabilize G-quadruplex structures that are formed from duplex human telomeric DNA as well as those formed from single-stranded DNA. Interestingly, telomestatin has a 70-fold higher selectivity for intramolecular G-quadruplex structures over duplex DNA. A recent study using an in-gel hybridization technique has shown that telomestatin has a dramatic effect on the conformation of intracellular 3 0 overhangs (Gomez et al., 2004 ). Telomestatin appears to be very promising as a telomere-directed compound because of its higher selectivity toward G-quadruplexes compared with all other nucleic acid conformations (Rosu et al., 2003) .
The telomere-binding proteins TRF1 and TRF2 are major regulators of telomere stability (Smogorzewska et al., 2000) . Both proteins have a Myb-like helix-turnhelix domain in their C-termini and a central conserved domain that is responsible for the formation of homodimers (Broccoli et al., 1997) . TRF1 and TRF2 differ at their N-termini, where TRF1 has an acidic domain and TRF2 a basic domain. Overexpression of TRF1 or TRF2 in cancer cells induces a gradual loss of telomeres at a rate of B10 bp/population doubling levels (PDLs). Overexpression of a dominant-negative mutant allele of TRF1, which removes endogenous TRF1 from telomeres, leads to telomere elongation. Conversely, expression of a dominant-negative mutant allele of TRF2, TRF2 DBDM , in human cells results in loss of the 3 0 overhang of telomeres, chromosome end-to-end fusions, and activation of the ATM/p53 DNA damage response pathway (Karlseder et al., 1999 ). An electron microscopy study has shown that TRF2 itself has the ability to remodel telomeric DNA into a 't-loop' (Stansel et al., 2001) , in which the single-stranded guanine-rich terminus invades the duplex region of the telomere (Griffith et al., 1999) . This study demonstrates that telomestatin induces dissociation of TRF2 from telomeres, resulting in the loss of telomeric 3 0 overhangs in cancer cells. In contrast, this agent did not induce TRF2 dissociation from telomeres or the loss of telomeric 3 0 overhang in normal or hTERT-immortalized cells, which showed normal characteristics after treatment. Based on these findings, we propose a new mechanism for t-loop formation that involves G-quadruplex DNA and TRF2 proteins.
Results
Telomestatin inhibits cell growth in cancer cells but not in normal fibroblasts and epithelial cells without reduction of telomerase activity Before treatment of cultured cells with telomestatin, in order to confirm the effects of telomestatin on telomerase activity in a cell-free system, we performed a conventional nonradioisotope TRAP assay using S-100 extracts from the SiHa cancer cell line (1000 cells/assay). Telomestatin was premixed with the S-100 extracts of SiHa before adding reaction buffer containing the TS primer, dNTPs and Taq polymerase. Telomerase activity was significantly inhibited by addition of 5 nM telomestatin ( Figure 1a) . These results showed that telomestatin is a potent inhibitor of telomerase activity and were consistent with the previous report (Kim et al., 2002) .
To determine the effects of telomestatin on cell growth, we used the human cervical adenocarcinoma cell line HeLa, the human breast cancer cell line MCF-7, the human cervical cancer cell line SiHa, normal fibroblasts MRC-5, hTERT-immortalized fibroblasts MRC-5-hTERT and human breast epithelial cells 90p. These cells were cultured in the presence of telomestatin at concentrations of 0-10 mM. In the long-term treatments (Figure 1b) , cell growth was gradually inhibited by 2.5 mM of telomestatin in both cancer cells and hTERT-immortalized fibroblasts. Human breast epithelial cells have limited proliferative capacity in an in vitro culture system, and cannot be maintained over 20 PDLs, and thus long-term culture is impossible. However, we used these cells as a normal control for short-term treatments, as described later in the Figures 1(e, f) , 3, 4 and 6. Although there were not significant differences in telomestatin effects at concentrations below 2.5 mM between cancer cell lines and normal cells (Figure 1b) , when cells were treated with 5 or 7.5 mM telomestatin, growth of the cancer cell lines SiHa, HeLa and MCF-7 was severely inhibited (Figure 1c) , whereas MRC-5-hTERT growth could be maintained under these conditions for over 40 days. Upon closer examination of the effect of telomestatin on cell viability, we found significant differences in survival rates after telomestatin treatments (5 mM), as 90% of cells from cancer cell examined were dead within 1 week, whereas normal epithelial cells 90p and hTERT fibroblasts MRC-5-hTERT were not killed by this treatment (Figure 1e ). When the normal MRC-5 fibroblasts were treated with 5 mM telomestatin, they showed growth curves as similar to those of hTERT-immortalized cells, MRC-5-hTERT, until the former cells entered senescence (data not shown).
At higher concentrations of telomestatin, MRC-5-hTERT proliferated for over 5 weeks (at 5 mM) but the other cells ceased proliferation more rapidly. Short-term treatments showed a clear difference in sensitivity to telomestatin between cancer (SiHa, HeLa, and MCF-7) and noncancer (MRC-5 and MRC-5-hTERT) cell lines (Figure 1d and e). Cancer cell lines died by 10 days in the presence of telomestatin at concentrations over 5 mM, whereas noncancer cells remained viable for much longer (over 5 weeks). In contrast, normal cells displayed a healthy, normal morphology after treatment with telomestatin ( Figure 1f ). These results show clearly that the cancer cell lines used here are more sensitive to telomestatin than noncancer cell lines. Furthermore, this difference between normal and cancer cell lines, and the Telomestatin was added to a CHAPS extract from the SiHa cancer cell line equivalent to 1000 cells, then mixed with TRAP reaction buffer containing TRAP buffer, dNTPs, the TS primer and Taq DNA polymerase, before performing the TRAP-PCR reaction as described previously. PCR products were separated on a 12% acrylamide gel in 0.5 Â TBE buffer, stained with SYBR Green I, and visualized with Fuji FLA-2000. An internal telomerase assay standard (ITAS) was used for internal control of the TRAP assay. (b) SiHa, MCF-7, HeLa, and MRC-5-hTERT cells were propagated in the presence of telomestatin at 0-10 mM. Growth curves of long-term telomestatin-treated cells at different concentrations (0-10 mM). PDLs: population doubling levels. (c) Growth curves of short-term telomestatin-treated cells at 5 mM concentration. PDLs: population doubling levels. (d) Days to induction of cell death after short-term telomestatin (2.5 and 5 mM) treatments. In HeLa, MCF-7, MRC-5-hTERT cells, cell death was not induced even after over 100 days. MRC-5 normal cells, cultured either with or without telomestatin, grew gradually and senesced after around 40 days. Telomestatin does not induce significant telomere attrition in either cancer or noncancer cells under the short-term conditions Previous studies have shown that telomerase inhibitors induce a gradual loss of telomere length in telomerase positive cancer cells without affecting cell growth, until the cells reach their limit of telomere shortening. Thus, telomestatin may also induce telomere shortening after longer time periods, and the times of death may therefore depend on telomere length limits that are specific for each cell line.
To examine the effects of telomestatin on telomere length and telomerase activity, the CHAPS extracts from HeLa cells cultured for 200 days in the presence of telomestatin were collected to measure their telomerase activity, and genomic DNA was purified for telomere length analysis. To ensure the accurate measurement of telomerase activity between telomestatin-treated and nontreated cells, the TRAP assay was performed on serially diluted samples (10 3 , 10 2 , 10 cells/assay). There were no significant differences in telomerase activity between them. The telomerase activity was almost equal among cells treated with telomestatin concentrations up to 2.5 mM (Figure 2a ). Although SiHa cells could only survive 20 days in the presence of 2.5 mM telomestatin, the telomerase activity did not change under this condition ( Figure 2b ). Additionally, similar results showing that telomerase was active in telomestatintreated cells were obtained in other cell lines including cancer, HeLa, MCF-7, and immortal noncancer cells (data not shown). These results seem to contradict the results shown in Figure 1a , in which telomestatin at 5 nM was enough to inhibit telomerase activity. However, since telomestatin is known to interact with telomeric 3 0 overhang DNAs but not with the telomerase enzyme itself, telomerase activity was viable in the S-100 extracts of telomestatin-treated cells.
While telomestatin did not affects the telomerase activity, telomere length was decreased by long-term treatment with telomestatin at 2.5 mM in HeLa (for 270 days) and MRC-5-hTERT (for 260 days) cells, whereas no significant reduction of telomere length was observed in MCF-7 (for 280 days) after treatment ( Figure 2c ). Since SiHa cells were sensitive to telomestatin, we applied 1 mM of the drug for 60 days, but the telomere length was not altered under this condition ( Figure 2c ). There was no significant difference in total telomere length after short-term treatment with telomestatin ( Figure 2d ).
When SiHa, HeLa and MCF-7 cells were treated with 5 mM telomestatin, rapid inhibition of cell growth followed by cell death was observed ( Figure 1e ). In contrast, telomestatin did not inhibit cell growth in normal fibroblasts and hTERT-fibroblasts until 3 weeks, and the cells survived for 40 days ( Figure 1c ). TRF (telomere restriction fragment) length did not shorten even at the point of cell death in both cancer cell lines (SiHa and HeLa) and MRC-5-hTERT cells ( Figure 2d ). These results indicate that telomestatin specifically induces rapid cell death in cancer cells under short-term conditions described here without affecting the telomere length.
Telomestatin induces reduction of 3 0 telomeric overhangs Recent reports have shown that reduction of the 3 0 telomeric overhang is involved in apoptosis associated with DNA damage signaling (Karlseder et al., 1999; Stansel et al., 2001 ). In addition, telomestatin was reported to interact with the single-stranded telomeric 3 0 overhang rather than with the double-stranded telomere DNA (Kim et al., 2003; Gomez et al., 2004) , and it induced the loss of the telomeric 3 0 overhang in cancer cells, as seen using in-gel hybridization analysis (Gomez et al., 2004) .
Although significant telomere shortening was not observed after short-term treatment with telomestatin ( Figure 2c ) even when the cells were treated at higher concentrations ( Figure 2d ), it is possible that the telomeric 3 0 overhang is in fact reduced, thereby inducing rapid cell death following t-loop destruction due to single-stranded telomere attrition. To examine the effects of telomestatin on telomeric 3 0 -overhang more quantitatively, for example to search for a possible correlation between G-tails loss and the sensitivity of cells, development of more sensitive and quantitative methods will be required. Recently, we developed the Gt-Telomere HPA (G-tail Telomere Hybridization Protection Assay) to measure the length of telomeric 3 0 overhangs (Tahara et al., 2005) . This method is a single tube-based assay requiring only 5 mg of genomic DNA, it involves only three steps carried out within 40 minutes, and it is specific, sensitive and quantitative for mammalian telomeric G-tails. To measure the telomeric 3 0 overhang, nondenatured genomic DNA, typically 5 mg DNA, was used so that the telomere-HPA probe would hybridize only with the 3 0 overhang single-stranded telomeric sequences. To test the linearity of this method, we used telomere repeat oligonucleotides, telomere 84mer, 5 0 -(TTAGGG) 14 -3 0 , as a quantitative standard to construct an analytical curve for Gt-telomere HPA. We found that there was good linearity in the range between 1 Â 10 À7 mM and 5 Â 10 À5 mM telomere 84 mer oligo (Tahara et al., 2005) . Since the telomere-HPA probe exhibits strict sequence specificity, one mismatch sequence within the hybridization region of an HPA probe would be sufficient to hydrolyse the acridinium ester label at the hydrolyzation step, due to the lack of protection by double-stranded DNA. In this assay, 'total' telomere length, including both double-stranded DNA and the single-stranded 3 0 telomeric overhang, was measured using denatured genomic DNA before hybridization with the telomere-HPA probe, which specifically hybridizes with telomeric DNA sequence repeats, 5 0 -TTAGGG-3 0 , as described before (Nakamura et al., 1999) .
When SiHa cells were treated with telomestatin at 5 mM for 48 h, a remarkable reduction of the 3 0 overhang Telomestatin dissociates TRF2 from telomeres H Tahara et al telomere length was observed (Figure 3a ). Other cancer cell lines, MCF-7 and HeLa, also showed a reduction of the 3 0 overhang telomere length. On the contrary, no reduction of the 3 0 overhang telomere length was detected in hTERT-immortalized cells and human breast epithelial cells 90p under the same conditions of telomestatin treatment (Figure 3a ). The reduction rates for the telomeric 3 0 overhang were 32, 46 and 21.4% in HeLa, SiHa and MCF-7, respectively. The effect of telomestatin on cell growth was compared with the reduction rate of the telomeric 3 0 -overhangs (Figure 1e ), and found to be strongly correlated. To test the specificity of this method, nondenatured genomic DNA was treated with ExonucleaseI (ExoI), which is known to remove nucleotides from single-stranded DNA in the 3 0 -5 0 direction. As shown in Figure 3a , ExoI treatment ( þ ) did decrease the 3 0 overhang telomere signals to the background levels, confirming that this Gt-telomere HPA method was able to specifically measure the 3 0 overhang telomere length. Since it is suggested (Gomez et al., 2004 ) that telomestatin tenaciously remains bound to telomeric DNA even after genomic DNA is extracted from telomestatin-treated cells, it is required to show whether Figure 2 Effect of telomestatin on telomerase activity and telomere length. (a) HeLa cell lines were maintained in the absence or presence of telomestatin at the indicated concentrations. Extracts from 1000, 100 and 10 cells were used for each assay. Cells were collected after 200 days of treatment with telomestatin, and a telomerase assay was performed using a non-RI TRAP assay. PCR products were separated on 12% acrylamide gels in 0.5 Â TBE buffer, stained with SYBR Green, and visualized with Fuji FLA-2000. DMSO-treated cells were used as a control. ITAS, an internal control for the PCR reaction, was used for the TRAP assay. (b) The SiHa cell line was maintained in the absence or presence of telomestatin at the indicated concentrations. Cells were collected after 20 days of treatment with telomestatin, and a telomerase assay was performed using a non-RI TRAP assay. Extracts from 100 and 10 cells were used for each assay. PCR products were separated on 12% acrylamide gels in 0.5 Â TBE buffer, stained with SYBR Green, and visualized with Fuji FLA-2000. ITAS, an internal control for the PCR reaction, was used for the TRAP assay. (c) Effect of telomestatin on telomere length in long-term telomestatin-treated HeLa, MCF-7, SiHa, and MRC-5-hTERT cells. Genomic DNA was isolated from cells cultured with/without telomestatin for the indicated number of days. Telomeric restriction fragments (TRFs) were detected by Southern blotting using the TeloTAGGG telomere detection system. (d) Effect of telomestatin on telomere length in shortterm telomestatin-treated HeLa, SiHa and MRC-5-hTERT cells. The cells were treated with telomestatin at the indicated concentrations for 2, 3 and 5 days, respectively. TRFs were detected by Southern blotting using the TeloTAGGG telomere detection system. Telomestatin dissociates TRF2 from telomeres H Tahara et al the apparent reduction of relative light units (rlu) value of Gt-telomere HPA in telomestatin-treated cells is due to the shortening of G-tail or the occupancy at G-tail by telomestatin. The rlu value (8575) of Gt-telomere HPA in nontreated SiHa cell extract was identical to the rlu value (8554) in telomestatin pretreated (5 mM for 3 h) extract. Although we did not measure the real amount of telomestatin possibly remained in pretreated cells or in DNA from pretreated cells, it does not affect on this assay under our conditions. We also measured total telomere length using the Telomere HPA method under denaturing conditions (Figure 3b ). Consistent with the results shown in Figure 2d , there was no significant difference in total telomere length after short-term treatment with telomestatin (Figure 3b) . Since 3 0 single-stranded telomere length is reported to be around 200 bases, which is much shorter than the total telomere length, attrition of the 3 0 overhang due to telomestatin treatment seems to have no effect on the total length of telomeres. Supposing that the mean telomere length (TRF) of SiHa is around 4 kb and the 3 0 overhang length is 200 bases, ratio of 3 0 overhang to TRF would be around 5%. As expected, the HPA assay gave the value of 5.2%. Taken together, these results indicate that telomestatin induces loss of the 3 0 overhang without affecting the length of doublestranded telomeric DNA, and that the rate of G-tails loss is well correlated with the effects of telomestatin on cell viability.
Telomestatin dissociates TRF2 from telomeres
Reduction of the 3 0 overhang and subsequent apoptosis is an effect reminiscent of results obtained for dominantnegative TRF2, which were previously reported by the group of Titia de Lange (van Steensel et al., 1998) . Transfection of dominant-negative TRF2, TRF2 DBDM , induces the dissociation of TRF2 protein from telomeres, followed by chromosome fusion, anaphase bridge formation and apoptosis or senescence (van Steensel et al., 1998) .
Since telomestatin is a potent telomerase inhibitor that binds to the telomeric G-quadruplex, it is plausible that telomestatin affects the association of telomerebinding proteins to telomeres. To explore this possibility, we examined the interactions of telomeric DNA and telomere-binding proteins by using a telomere-chromatin immunoprecipitation (ChIP) assay. TRF2 protein levels in both cancer cell lines and normal cells were confirmed by Western blotting, which showed that SiHa cells as well as other cancer cell lines had significant levels of the TRF2 protein (Figure 4a) . In normal cells including MRC-5-hTERT and 90p, we could detect TRF2 protein, but the level of TRF2 expression was lower than in cancer cells. These results were consistent with another report that TRF2 expression is higher in cancer cells than normal cells (Nakanishi et al., 2003; Gu et al., 2005; Nijjar et al., 2005) , but the mechanism is still unclear. We performed a ChIP assay using SiHa, MCF-7, HeLa and 90p cells, and all samples were normalized with Alu DNA as described in Materials and 0 telomeric overhangs were measured by Gt-telomere HPA. Nondenaturing genomic DNA (5 mg) was treated with (ExoI þ ) and without (ExoIÀ) exonuclease I, then mixed with an acridinium ester labeled telomere HPA probe at 601C for 20 min; unhybridized probes were hydrolysed with hydrolyzation buffer at 601C for 10 min. Luminescence of telomere HPA probes hybridized to telomeric 3 0 overhangs was measured using a luminometer (GenProbe). Each experiment was performed in duplicate. (b) Effect of telomestatin (5 mM, 48 h) on total telomere length in HeLa, SiHa, MCF-7, MRC-5-hTERT and 90p cells. Total telomere lengths were measured by telomere HPA. Denaturing genomic DNA (1 mg) was mixed with an acridinium ester labeled telomere HPA probe at 601C for 20 min; unhybridized probes were hydrolysed with hydrolyzation buffer at 601C for 10 min. Telomere HPA probes hybridized to telomere DNA were counted using a luminometer (Gen-Probe). Each experiment was performed in duplicate.
H Tahara et al methods. As shown in Figure 4b , telomeric DNA was precipitated from SiHa cells with an anti-TRF2 antibody (IMG-124, IMGENEX). Strikingly, however, telomestatin-treated SiHa cells gave no telomere ChIP signal when assayed with the same antibody. An anti-bactin antibody, used as a negative control antibody, did not precipitate telomere DNA in either telomestatintreated or nontreated cells (Figure 4b ). In contrast, anti-TRF1 antibodies precipitated telomere DNA in both telomestatin-treated and nontreated SiHa cells (Figure 4c ). Other cancer cell lines, MCF-7 and HeLa, also showed reduced binding of TRF2 after being treated with telomestatin at 5 mM (Figure 4b and c) .
Semi-quantitative analysis by the telomere-ChIP assay clearly showed that TRF2 proteins specifically and dramatically dissociated from telomeres in telomestatintreated SiHa cells (Figure 4b and c) . A slight amount of TRF1 dissociation from telomeres was also observed in telomestatin-treated SiHa cells. However, the dissociation of TRF2 from telomeres was much more drastic than that of TRF1. The amount of TRF2 did not change after telomestatin treatment in normal cells or in cancer cells (Figure 4a ). The effects of telomestatin on TRF2 binding (Figure 4c ) and the reduction of telomeric 3 0 -overhang (Figure 3a) , were well correlated (Figure 4d) , and thus these results suggest that telomestatin-induced TRF2 dissociation is accompanied by loss of the telomeric 3 0 -overhang. To confirm the results of these telomere-ChIP analyses, we performed immunofluorescence staining using the same antibodies used in the telomere-ChIP experiments ( Figure 5 ). As expected, TRF2 foci in SiHa were decreased by treatment with telomestatin at 5 mM for 48 h (Figure 5a ). TRF1 foci in SiHa cells were not altered by telomestatin treatments, while TRF1 and TRF2 were colocalized in control cells (Figure 5b ). TRF2 protein levels in MRC-5-hTERT cells were quite low as compared with cancer cell lines (Figure 4a) , and we could not detect telomere association with either TRF1 or TRF2 in MRC-5-hTERT fibroblasts by telomere-ChIP analysis (data not shown). However, TRF2 foci were detected in the nuclei of these normal and hTERT-immortalized fibroblasts by fluorescence staining (Figure 5c ). Interestingly, signals of TRF2 foci in both normal MRC-5 and MRC-5-hTERT cells were not altered by telomestatin treatment. Telomestatin did not affect the signals of TRF1 foci, either. These results suggest that telomestatin that stabilizes G-quadruplex structures in single-stranded telomeric 3 0 -overhangs does not induce the dissociation of TRF2 from telomeres in Figure 4 Effect of telomestatin on the association of telomerebinding proteins to telomeric DNA. (a) TRF2 protein expression in telomestatin-treated cancer and normal-derived hTERT cells. Cell lysates were prepared from each cell line with ( þ ) or without (À) telomestatin treatments (5 mM, 48 h), and 30 mg of protein was run on a 10% acrylamide SDS denaturing gel, then transferred onto a Hybond P membrane. A primary anti-TRF2 antibody (IMG-124, IMGENEX) was used. b-Actin was used as an internal control. (b) Telomere-ChIP assay with TRF2 and b-Actin antibodies. Cells were fixed with formaldehyde for 10 min and were then sonicated. Sonicated samples were immunoprecipitated with antibodies, and the precipitants were blotted onto a Hybond-N membrane. Total sample (10%) was applied for input. The filter was hybridized with a DIG-labeled telomere probe, 5 0 -(TTAGGG) 4 -3 0 , and hybridized telomeric DNA was detected using the TeloTAGGG telomere detection system. b-Actin antibody was used as a negative control. normal and hTERT-fibroblasts cells, and that TRF2 dissociation from telomeres is specific to cancer cell lines.
Telomestatin induces anaphase bridge formation and apoptosis in cancer cells, but not in normal cells
Telomestatin-induced rapid cell death in cancer cells but not in normal cells (Figure 1e) , and it induced TRF2 dissociation from telomere DNA accompanied by a rapid loss of the telomeric 3 0 overhang in SiHa cancer cells (Figure 3a) . Introduction of dominant-negative TRF2 was reported to induce telomeric 3 0 overhang loss accompanied by Telomere Dysfunction-Induced Focus (TIFs), anaphase bridge and apoptosis (Karlseder et al., 1999; Stansel et al., 2001; Takai et al., 2003) . Among these typical phenotypes, we further examined anaphase bridge formation and apoptosis in telomestatin-treated cells. Anaphase bridges were found in telomestatintreated SiHa, HeLa and MCF-7 cancer cell lines, but we could not find any anaphase bridge formation in MRC-5-hTERT fibroblasts or in the human epithelial cells 90p (Figure 6 ). Typical anaphase bridge formation is shown in Figure 6b . Again, a good correlation was found between the rate of TRF2 dissociation from telomeres and the rate of anaphase bridge formation. We next examined whether telomestatin induces apoptosis at concentrations sufficient for inducing telomeric 3 0 overhang loss in SiHa cancer cells. Upon treatment with 5 mM of telomestatin, SiHa cancer cells showed TUNELpositive fractions whereas MRC-5-hTERT did not show TUNEL positive cells (Figure 7e and n) . These results suggest that telomestatin induces apoptosis accompanied by 3 0 overhang telomere loss in cancer cells but not in normal or hTERT-immortalized cells. This is consistent with the results showing that cancer cell lines 
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H Tahara et al were much more sensitive than normal cells to telomestatin-induced dissociation of TRF2 from telomeres (Figures 4(b, c) and 5). These results also suggest that telomere regulation by telomere-binding proteins may be different in normal cells and cancer cells.
Discussion
G-quadruplex interacting agents can facilitate and stabilize the formation of G-quadruplexes. G-quadruplex formation has been shown to directly inhibit telomerase elongation in vitro. Telomestatin has a 70-fold higher selectivity for intramolecular G-quadruplex structures over duplex DNA (Kim et al., 2003) . Optimal telomerase activity requires the nonfolded, singlestranded form of primers in vitro. Thus, stabilization of G-quadruplexes formed at the telomeric 3 0 overhangs at chromosome ends should inhibit telomere elongation by telomerase. In this study, we found that telomestatin, a G-quadruplex interacting agent, dissociated TRF2 proteins from telomeres and induced apoptosis through rapid loss of the telomeric 3 0 overhangs. These results are quite interesting because telomestatin not only affects telomere elongation by telomerase, but it also facilitates TRF2 dissociation from telomeres, which may induce disruption of t-loops as well as anaphase bridge formation. Thus, telomestatin seems to have dual functions that both result in telomerase inhibition. It is also interesting that the TRF2 protein, but not TRF1, was specifically dissociated from telomeres by treatment with telomestatin. TRF1 and TRF2 have a homologous architecture defined by two conserved domains, a TRFH domain that mediates homodimerization in both proteins and a Myb DNA-binding domain that is essential for binding to telomere double-stranded DNA. Despite their extensive homology, TRF1 and TRF2 do not heterodimerize, and each interacts with distinct set of binding proteins. TRF1 protein complexes in telomeres contain TIN2, TPP1 (formerly called as PIP1/PTOP/TINT1) and POT1, whereas the TRF2 protein interacts with TIN2, RAP1, the Rad50/ MRE11/NBS complex and the DNA PK, Ku70/Ku80 complex. Yeast RAP1 protein and the b-subunit of the Oxytricha telomere-binding protein not only bind to G-quadruplexes but also facilitate the formation of these structures (Fang and Cech, 1993a, b; Giraldo et al., 1994) . Thus, telomestatin may also influence not only the TRF2 protein but also other telomereassociated proteins.
While telomestatin removes TRF2 protein from telomeres and induces telomere dysfunction, other binding proteins may also be good targets for induction of telomere dysfunction. In fact, PARP inhibitors that inhibit tankyrase 1 enhance telomere shortening by a telomerase inhibitor and hasten cell death (Seimiya et al., 2005) . The combination of tankyrase and telomerase inhibitors may offer new opportunities for realizing the promise of telomerase inhibition therapy (Shay and Wright, 2005) . This strategy can be modified to create combination cancer therapies using telomestatin and other drugs, including telomerase inhibitors and molecular targeting anticancer drugs.
The TRF2 protein preferentially dissociated from telomeres as compared with the TRF1 protein, even though the DNA-binding mode of TRF2 is most likely identical similar to that of TRF1. However, a recent study has shown that TRF1 binds more strongly to telomere DNA than the TRF2 because TRF2 Myb domain has weaker DNA-binding activity than the TRF1 Myb domain (Hanaoka et al., 2005) . This may be the reason that TRF2 is more sensitive to dissociation by telomestatin than TRF1. The formation of G-quadruplex structures has been proposed as the Telomestatin dissociates TRF2 from telomeres H Tahara et al molecular mechanism that affords 3 0 overhang protection (Han and Hurley, 2000) . Griffith and de Lange have demonstrated using electron microscopy that TRF2 proteins can remodel telomeric DNA into large duplex loop (t-loop) in vitro (Griffith et al., 1999) , and various models of t-loop formation involving G-quadruplex DNA have been proposed (Han and Hurley, 2000) . For example, the 3 0 overhang can fold over to form an intramolecular G-quadruplex (Williamson et al., 1989) . Thus, telomestatin that stabilizes G-quadruplex structures may affect t-loop formation as well as TRF2 binding. Although telomestatin induces TRF2 dissociation from telomeres and apoptosis accompanied by t-loop disruption in cancer cells, it does not induce anaphase bridges in sea urchin embryos (Kim et al., 2003) . Another G-quadruplex interacting agent, TMPyP4, induces anaphase bridges in sea urchin embryos (Kim et al., 2003) . In addition, telomestatin, but not TMPyP4, increases DNA cleavage by S1 nuclease at both loop regions in an asymmetric way in a G-quadruplex structure (Kim et al., 2003) . This is a possible reason that telomestatin induces the loss of 3 0 overhangs followed by TRF2 dissociation from telomeres.
In this study, we found that telomestatin-induced dissociation of the TRF2 protein from telomeres and cell death preferentially in cancer cell lines. Our future studies will include experiments to clarify why TRF2 dissociation from telomeres by telomestatin is particularly effective in cancer cells. A better understanding of the G-quadruplex structure, its associated proteins including TRF2/TRF1, and other proteins such as Pot1 may be important to answer this question. TRF2 expression is higher in cancer cells and tumor tissues than in normal cells as shown in Figure 5a and previous reports (Nakanishi et al., 2003; Gu et al., 2005; Nijjar et al., 2005) . Although the mechanism of TRF2 upregulation in cancer cells is unclear, it is possible that TRF2 overexpression may cause higher sensitivity to telomestatin, and that this in turn causes TRF2 dissociation form telomeres. Inhibition of TRF2 function resulted in apoptosis in a subset of mammalian cell types, and the response was mediated by p53 and the ATM (ataxia telangiectasia mutated) kinase, consistent with activation of a DNA damage checkpoint (Karlseder et al., 1999) . Telomestatin-induced apoptosis may also be mediated by p53 and the ATM kinase. Telomeric DNA lacking TRF2 directly triggers an apoptosis signal due to rupture of dicentric chromosomes formed by endto-end fusion, and therefore telomestatin may be a direct DNA damage inducer in cancer cells.
In conclusion, the data we have presented here suggest that telomestatin inhibits TRF2 binding to telomeres and induces t-loop disruption followed by 3 0 overhang loss, and that this in turn results in rapid apoptosis in cancer cells. In addition, telomestatin at 5 mM did not affect normal or hTERT-immortalized fibroblasts within a month. These findings suggest that G-quadruplex structures are involved in t-loop and/or d-loop stability as well as in TRF2 binding to telomeres. t-Loop and/or d-loop stability may differ between normal cells and cancer cells, because cancer cell lines are much more sensitive to telomestatin than are normal cells. These results also imply that G-quadruplex stability may involve t-loop structures that are associated with TRF2 binding to telomeres. The TRF2 protein as well as other telomere-capping proteins appear to be compelling anticancer drug targets that may be exploited to kill cancer cells effectively and more rapidly.
Materials and methods

Cell culture and reagents
The MCF-7 human breast cancer cell line, SiHa human cervical cancer cell line, and HeLa human cervical cancer cell line, were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Hyclone, USA). These cancer cell lines are derived from cancer tissues. Human normal fibroblasts, MRC-5, and its immortal derivative line by hTERT infection, MRC-5-hTERT, were maintained in Dulbecco's modified Eagle's medium DMEM F12 (Invitrogen) supplemented with 10% fetal bovine serum (Hyclone, USA) and SAP. Human breast epithelial cells, 90p, were maintained in MEGM BulletKit (Cambrex, Inc.). MRC-5 and 90p are derived from normal tissues. MRC-5-hTERT cell did not show any cancer phenotype such as colony formation in soft agar and tumor formation. Telomestatin was dissolved in methanol at 10 mM concentration first, then an equal volume of DMSO was added and it was stored at À201C.
Telomerase assay
Telomerase activity was measured by modified TRAP as described previously (Tahara et al., 1995) . Briefly, cells were collected at 100 000 cells/tube and extracted using a CHAPS lysis buffer. Each extract equivalent to 1000 cells was mixed with/without telomestatin and then mixed with the TRAP reaction buffer containing the TS primer, dNTPs and Taq DNA polymerase, and incubated at 251C for 30 min. After the telomerase reaction, the CX primer was added to each tube and a PCR reaction was performed as described previously (Nakayama et al., 1998) . TRAP products were run on a 12% acrylamide nondenaturing gel with 0.5 Â TBE buffer, stained with SYBR green I for 10 min, and visualized with Fuji FLA-2000 (Fujifilm).
Telomere length assay by Southern blotting Genomic DNA for measuring telomere length was isolated from each cell line using the phenol-chloroform extraction method. In brief, cells were scraped and pelleted in microtubes by centrifugation at 6000 r.p.m., 41C for 5 min in an Eppendorf microcentrifuge. Pellets were washed once with PBS (À) and were suspended in extraction buffer containing 10 mM Tris (pH 7.6) and 150 mM NaCl, then NP-40 was added at a final concentration of 0.5%. After Proteinase K treatment, phenol-chloroform extraction was performed twice. After the suspension was treated with RNase A, genomic DNA was precipitated with ethanol and dissolved in TE buffer. Telomere length was measured using the TeloTAGGG Telomere length assay kit according to manufacturer's instructions (Roche Diagnostics).
Telomere-ChIP assay ChIP was carried out using a Chromatin IP (ChIP) assay kit, following the protocol described by the manufacturer (Upstate). After precipitation with antibody, the precipitants were blotted onto a Hybond-N membrane (Amersham), and telomere repeat sequences were detected with a TeloTAGGG telomere length assay kit (Roche Diagnostics). Telomere signals were semiquantitated with Fuji FLA-2000(Fujifilm) . Before the ChIP experiments were carried out to normalize the DNA amount in each assay, one-tenth of the amount of in-put samples used in each ChIP assay was hybridized with 3 Â 10 6 rlu of the AE-labeled Alu probe. The luminescence signals were normalized using the Alu signals, and arbitrary units were plotted. Details of the method for measuring Alu DNA using HPA were described before (Nakamura et al., 1999) .
Western blotting
Cells were extracted with RIPA buffer and using a 21G syringe five times, and extracts were kept on ice for 30 min. Clear lysates were collected after centrifugation at 14 000 r.p.m., 41C for 20 min. Samples were stored at À801C until use. Typically, 30 mg of cell lysates were applied to each lane. Samples were separated with 10% NOVEX NuPAGE Bis-Tris gels as per the manufacturer's protocol. Transfer was performed with an XCell II Blot Module using a Fluorotrans western membrane (0.2 mm, PALL). Mouse monoclonal antibodies (IMG-124, IMGENEX, 0.002 mg/ml) were used to detect the TRF2 protein. A horseradish peroxidase linked anti-mouse IgG (1.0 Â 10 5 times dilution, NA931V, Amersham Biosciences) was used as the second antibody and bands were detected using the ECL plus detection system (Amersham Biosciences).
Immunofluorescence
The cells were treated with telomestatin at 5.0 mM concentration for 48 h at 371C. They were then fixed with 2% paraformaldehyde in PBS for 10 min and permeabilized with 0.5% NP-40/PBS. Indirect immunofluorescence staining was performed as described previously (Seimiya et al., 2004) , using the primary mouse antibody anti-TRF1 and/or TRF2 (IMG-124, IMGENEX) and affinity purified rabbit anti-TRF1 (5747, 1 mg/ml) (Seimiya et al., 2004) .
Quantification of telomere length and telomere 3 0 single-stranded overhang by the G-tail telomere hybridization protection assay (Gt-telomere HPA) Quantification of total telomere length (both double-stranded and single-stranded) was carried out using Telomere HPA methods as described previously (Nakamura et al., 1999) . To detect telomere 3 0 overhangs, we used the recently developed Gt-Telomere HPA method, as described (Tahara et al., 2005) .
The HPA procedure used to quantify telomere repeats was based on a method described previously to measure telomerase activity and telomere length Nakamura et al., 1999) . DNA, 1 mg, was required to measure total telomere length, and 5 mg of DNA was used to measure the 3 0 single-strand telomere overhang. DNA solutions were heatdenatured for 5 min at 951C (in the assay to measure total telomere length). One hundred ml of 3 Â 10 6 rlu of AE-labeled probe (5 0 -CCC TAA CCC TAA CC*C TAA CCC TAA CCCTA-3 0 ; *AE position) was added to denatured DNA (for the telomere length assay) or to nondenatured (for the 3 0 single-strand telomere overhang assay) in hybridization buffer (0.1 M lithium succinate buffer, pH 4.7, containing 200 g/l lithium lauryl sulfate, 1.2 M lithium chloride, 20 mM EDTA and 20 mM EGTA) and each reaction tube was incubated for 20 min at 601C (the probe sequence was corrected, and therefore differs from that described in the previous paper by Nakamura et al., 1999) . We next added 300 ml of selection buffer (0.6 mol/l sodium tetraborate buffer, pH 8.5, containing 50 ml/l TritonX-100) to differentially hydrolyse unhybridized probes during incubation for 10 min at 601C. Chemiluminescence was measured for 2 s per tube by a luminometer (Leader 1, Gen-Probe, Inc., San Diego, CA, USA). Alu sequences were also measured by HPA by using the following probe: 5 0 -TGT AAT CCC A*GC ACT TTG GGA GGC-3 0 (* AE position). Probes for AE-labeling of telomeres and detection of Alu sequences were supplied by Fujirebio Inc., Japan. (Tokyo).
Anaphase bridge formation Cells were fixed with 2% paraformaldehyde in PBS for 10 min, and stained with 4 0 ,6-diamidino-2-phenylindole (DPAI). The frequency of anaphase bridges was calculated as the ratio between cells exhibiting anaphase bridges and the total number of anaphase cells. At least 50 anaphase cells were examined in each experiment.
TUNEL assay TUNEL assays were performed using the DeadEnd Fluorometric TUNEL System (G3250, Promega Corp.) as per the manufacturer's protocol.
